Improving outcomes for children with malaria, diarrhoea and pneumonia in Mozambique through the inSCALE technology innovation: A cluster randomised controlled trial

3

4 Seyi Soremekun PhD#∞, Karin Källander PhD∞, Raghu Lingam MD, Ana-Cristina Castel Branco MSc, Neha Batura

5 PhD, Daniel Strachan PhD, Abel Muiambo MSc, Nelson Salomao MSc, Juliao Condoane MSc, Fenias Benhane MSc,

- Frida Kasteng MSc, Anna Vassall PhD, Zelee Hill PhD, Guus ten Asbroek PhD, Sylvia Meek PhD, James Tibenderana
 PhD*: and Betty Kirkwood PhD*
- 8
- 9 [#]Corresponding author
- 10 ∞Equal first author contribution
- 11 *Equal senior author contribution
- 12 [†]Deceased
- Seyi Soremekun[#]∞, Department of Infection Biology, London School of Hygiene & Tropical Medicine, Keppel
 Street, London, WC1E 7HT, United Kingdom. Seyi.Soremekun@lshtm.ac.uk
- Karin Källander∞, Malaria Consortium, The Green House, 244-254 Cambridge Heath Road, London, E2 9DA,
 United Kingdom & Department of Global Public Health, Karolinska Institutet, 17177, Stockholm, Sweden &
 UNICEF Programme Division, Health Section, New York, NY, United States. Karin.kallander@ki.se
- Raghu Lingam, Population Child Health Research Group, School of Women's and Children's Health,
 University of New South Wales. Australia. r.lingam@unsw.edu.au
- Ana-Cristina Castel Branco Malaria Consortium, Rua Joseph Ki-Zerbo 191, PO Box 3655, Coop, Maputo,
 Mozambique acastelbranco@clintonhealthaccess.org
- Neha Batura, Institute for Global Health, University College London, 30 Guilford Street, London WC1N 1EH,
 United Kingdom. <u>n.batura@ucl.ac.uk</u>
- Abel Muiambo Malaria Consortium, Rua Joseph Ki-Zerbo 191, PO Box 3655, Coop, Maputo, Mozambique
 a.muiambo@malariaconsortium.org
- Nelson Salomao Malaria Consortium, Rua Joseph Ki-Zerbo 191, PO Box 3655, Coop, Maputo, Mozambique
 n.salomao@malariaconsortium.org
- Juliao Condoane Malaria Consortium, Rua Joseph Ki-Zerbo 191, PO Box 3655, Coop, Maputo, Mozambique
 j.condoane@malariaconsortium.org
- Fenias Benhane Malaria Consortium, Rua Joseph Ki-Zerbo 191, PO Box 3655, Coop, Maputo, Mozambique
 f.benhane@malariaconsortium.org
- Frida Kasteng, Department of Global Health and Development, London School of Hygiene & Tropical
 Medicine, Keppel Street, London, WC1E 7HT, United Kingdom & Department of Global Public Health,
- 34 Karolinska Institutet, 17177, Stockholm, Sweden. frida.kasteng@ki.se

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- Daniel Strachan, Institute for Global Health, University College London, 30 Guilford Street, London WC1N
 1EH. United Kingdom & The Nossal Institute for Global Health, Melbourne School of Population and Global
 Health, The University of Melbourne Victoria, 3010, Australia. daniel.strachan@unimelb.edu.au
- Anna Vassall, Department of Global Health and Development, London School of Hygiene & Tropical
 Medicine, Keppel Street, London, WC1E 7HT, United Kingdom. <u>Anna.Vassall@lshtm.ac.uk</u>
- Zelee Hill, Institute for Global Health, University College London ,30 Guilford Street, London WC1N 1EH,
 United Kingdom. <u>Z.hill@ucl.ac.uk</u>
- Guus ten Asbroek, Department of Global Health, Amsterdam University Medical Centres, Meibergdreef 9
 1105 AZ Amsterdam, The Netherlands and Amsterdam Institute for Global Health and Development,
 Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands. a.h.tenasbroek@amsterdamumc.nl
- 45 Sylvia Meek⁺, Malaria Consortium, The Green House, 244-254 Cambridge Heath Road, London, E2 9DA,
 46 United Kingdom
- James Tibenderana*, Malaria Consortium, The Green House, 244-254 Cambridge Heath Road, London, E2
 9DA, United Kingdom. j.tibenderana@malariaconsortium.org
- Betty Kirkwood*, Department of Population Health, London School of Hygiene & Tropical Medicine, Keppel
 Street, London, WC1E 7HT, United Kingdom. <u>Betty.Kirkwood@lshtm.ac.uk</u>
- 51

52 Abstract

53 Background

54 The majority of post-neonatal deaths in children under 5 are due to malaria, diarrhoea and pneumonia (MDP). The

55 WHO recommends integrated community case management (iCCM) of these conditions using community-based

56 health workers. However iCCM programmes have suffered from poor implementation and mixed outcomes. We

57 designed and evaluated a technology-based intervention 'inSCALE' (<u>In</u>novations At <u>Scale For Lasting Effects</u>) to 58 support iCCM programmes and increase appropriate treatment and other outcomes for children with MDP.

59 Methods

This superiority cluster randomised controlled trial allocated all 12 districts in Inhambane Province in Mozambigue to 60 61 receive iCCM only (control) or iCCM plus the inSCALE technology intervention. The key components of the 62 intervention consisted of a digital application on smartphones and tablets providing clinical decision support algorithms, stock tracking, automatic personalised messaging, free calls, and solar chargers for iCCM-trained 63 community health workers and primary care facility supervising staff in intervention districts. Population surveys 64 65 were conducted at baseline and after 18 months in all districts to assess the impact of the intervention on the 66 coverage of appropriate treatment for malaria, diarrhoea and pneumonia in children 2-59months of age, on 67 prevalence of cases of these conditions, and on a range of secondary household and health worker level outcomes. All statistical models accounted for the clustered study design and variables used to constrain the randomisation. A 68 69 meta-analysis of the estimated pooled impact of the technology intervention was conducted including results from a

70 sister trial (inSCALE-Uganda).

71 Findings

72 The study included 2740 eligible children in control arm districts and 2863 children in intervention districts. The

73 prevalence of cases of MDP decreased from 53.5% (1467) to 43.7% (1251) in the control and intervention arms

respectively (risk ratio 0.82, 95% CI 0.78-0.87, p<0.001). The rate of care seeking to the iCCM-trained community

75 health worker increased in the intervention arm (14.4% vs 15.9% in control and intervention arms respectively) but

76 fell short of the significance threshold (adjusted RR 1.63, 95% CI 0.93-2.85, p=0.085). Coverage of the appropriate

treatment of cases of MDP increased by 26% in the intervention arm (RR 1.26 95% CI 1.12-1.42, p<0.001) after

accounting for the randomisation and design effects. Across two country trials, the estimated pooled effect of the

inSCALE intervention on coverage of appropriate treatment for MDP was RR 1.15 (95% CI 1.08-1.24, p < 0.001).

80 Interpretation

81 The inSCALE intervention led to a reduction in prevalence of MDP and an improvement in appropriate treatment

82 when delivered at scale in Mozambique. The programme will be rolled out by the ministry of health to the entire

83 national CHW and primary care network in 2022. This study highlights the potential value of a technology

84 intervention aimed at strengthening iCCM systems to address the largest causes of childhood morbidity and

- 85 mortality in sub-Saharan Africa.
- 86
- 87

88 Author Summary

- 89 The inSCALE cluster-randomised trial in Mozambique was part of a \$10million project funded by the Bill and Melinda
- 90 Gates Foundation to design and test innovative primary care interventions to improve health outcomes for children
- 91 with malaria, diarrhoea and pneumonia (MDP), which together are the largest killers of children aged <5yrs. The
- 92 study aimed to strengthen the primary health care system with a focus on community health workers, representing
- 93 the most accessible level of care for many underserved populations.
- We designed a technology-based intervention delivered using cheap smartphones. This intervention was based on mHealth principles and included basic AI to guide correct diagnosis and treatment of MDP, provided personalised feedback to health workers, and alerts to supervising health facilities on stock outs and data tracking. The study was implemented within the entire province of Inhambane, and districts were randomly assigned to the intervention or to continue with standard care (control). Compared to control districts, we observed significant reductions in the prevalences of MDP in children under 5 years (reductions of 20% for malaria, 34% for pneumonia, and 45% for diarrhoea) and an increase in appropriate treatment of any cases of MDP by 26% (of all cases MDP) and 40% (of all
- 101 children) in the intervention districts.
- As a result of this trial, the government of Mozambique incorporated the inSCALE intervention into its policy for child health services, and is in the process of scaling up the programme to all 8000+ community health workers across the
- 104 country (2022).

105 Introduction

More than 5 million mostly preventable deaths occur in children under 5 years of age every year(1). The vast 106 107 majority of post neonatal deaths in this group are due to pneumonia, diarrhoea, malaria or malnutrition(2). It is acknowledged that urgent work is required to address the causes and more widely, the systems within which such 108 109 deaths occur. However progress has been uneven; under 5 mortality rates in sub Saharan Africa today remain similar to or higher than 1990 mortality rates in most high income countries with an average rate of 78 deaths per 1000 live 110 births across the continent in 2018(2). Lack of access to timely and appropriate clinical management of sick children 111 is a key factor driving poor health outcomes(3,4) prompting a World Health Organisation/UNICEF joint statement in 112 2012 advocating for integrated community case management (iCCM) of malaria, diarrhoea and pneumonia delivered 113 by community-based lay health workers, who would be trained to diagnose and treat key childhood conditions in 114 areas with poor access to facility-based services (3). In the decade following this statement, iCCM programmes have 115 been introduced into more than 50 low- and middle-income countries (LMICs)(5–7). Whilst a recent multi-country 116 modelling study in DRC, Malawi, Niger, and Nigeria (8) estimated that iCCM may have been responsible for averting 117 118 nearly 5000 deaths per year in these countries combined due to malaria, diarrhoea and pneumonia, this estimate varied considerably between countries, and was in contrast to a Cochrane systematic review which found no clear 119 impacts of iCCM on morbidity and mortality(9). Both studies reported poor or uneven implementation of iCCM 120 programmes and a need for further studies that addressed structural deficiencies in health systems and processes 121 that hamper success and scale-up. 122

123 Central to the challenge in implementation of iCCM has been the lack of sufficient support for community-based 124 health worker (CHW) networks, low rates of CHW attrition, of reported motivation, and of quality of disease 125 management practices(10). The WHO calls for "innovative and tailored approaches" to strengthening child health 126 services (1), yet there are few programmes or even research studies which have explicitly addressed structural 127 barriers in the context of scaling up iCCM effectively.

Digital technologies, and specifically mHealth (the use of mobile technologies in medical and public health practice 128 129 (11) is an area of growing interest for the delivery of health services in sub-Saharan Africa (12,13) particularly given the rapid expansion of mobile phone networks and usage in this setting (14). In this paper we report on the 130 evaluation of a systems-strengthening package of programmes collectively called "inSCALE" (interventions at scale 131 132 for community access and lasting effects). inSCALE was a multi-country study of innovative interventions implemented by the Malaria Consortium in partnership with the governments of Mozambigue and Uganda and 133 supported by international funders (the Bill and Melinda Gates Foundation, UNICEF, and the Canadian international 134 135 Development Agency now Global Affairs Canada (GAC)) . Reported in this paper is findings of the "inSCALE technology intervention", a disease management support package that included electronic clinical decision 136 algorithms, personalised reports, messaging, and feedback to CHWs and health facility staff. The Mozambique site 137 tested the inSCALE technology intervention only; the Uganda site tested both the technology intervention and a 138 139 community-based intervention described elsewhere [Uganda ref]. The technology interventions in both countries 140 sought to specifically address primary health system challenges that could strengthen provision for key childhood 141 illnesses through improving CHW performance, motivation and reducing attrition. The primary aim of the trial was to

- assess the impact of the inSCALE technology intervention on the coverage of the appropriate treatment of childhood
 malaria, diarrhoea and pneumonia. This paper reports on the impacts of the technology intervention in Mozambique
 to accompany the separate impact analysis for the Uganda inSCALE trial [ref] and conducts a meta-analysis of pooled
 impact of the technology intervention across its sites in Uganda and Mozambique.
- 146

147 **Results**

- 148 In total 9231 households in the 12 districts were assessed for eligibility and of these, 495 were empty or no one was
- home, and 4483 did not contain children under 5 years of age. Overall, the main caretaker was available in 92%
- 150 (3920) of houses with children under 5 years of age. At the endline survey, a total of 2718 children had had
- 151 symptoms of MDP in the past month (the impact analysis sample), of which 1467 were in the control arm and 1251
- 152 in the intervention arm (Figure 1 flow chart). Household characteristics of sick children were fairly well balanced
- 153 between arms with small variations in some parameters Table 1.
- 154 The restricted randomisation method resulted in good balance between intervention arms for balance variables as
- described in the protocol paper(15), which were care seeking rates, CHW motivation, and cost of seeking care (Table
- 156 2). Differences for all variables was either less than 5% (percentages), or less than 0.1 (means).

158 **Table 1.** Characteristics of the inSCALE Mozambique study sample

Characteristic	Control % (n)	Technology % (n)
Eligible children	N = 2740	N = 2863
% children with MDP	53.5% (1467)	43.7% (1251)
% children with suspected malaria*	48.5% (1300)	39.8% (1118)
% children with confirmed malaria*	24.6% (661)	21.8% (612)
% children with diarrhoea**	7.2% (198)	4.2% (121)
% children with suspected pneumonia**	16.2% (443)	10.6% (304)
Children with MDP	N = 1467	N = 1251
% Respondent is mother of sick child	81% (1181)	83% (1036)
% children are boys	50% (733)	50% (629)
Age of mother		
12-19	10% (144)	8% (104)
20-29	38% (552)	37% (467)
30-39	28% (413)	30% (373)
40-49	12% (181)	14% (175)
50+	8% (113)	6% (76)
Not known	4% (64)	4% (56)
Highest education level completed (respondent)		
None	31% (453)	32% (400)
Incomplete primary	48% (706)	45% (557)
Primary or higher	21% (308)	24% (294)
Mother tongue		
Bitonga	17% (246)	6% (81)
Chitsua	54% (793)	72% (900)
Chichopi	17% (254)	19% (242)
Other	12% (174)	2% (28)
Marital status		
Married	2% (34)	3% (41)
Living with partner (not married)	78% (1151)	74% (929)
Single/divorced/widowed	19% (282)	22% (281)
% Main occupation is farming/fishing	75.9% (1113)	64.0% (801)

159

*Denominator is the 5490 children aged 4months – 5 years; **Denominator is the 5603 children aged 2m – 5 year

Table 2. Key indicators used to balance arms at baseline

Variables included in the restricted randomisation*	Control arm 662 children with MDP XX CHWs	Technology 658 children with MDP XX CHWs	Difference
Mean (log_{10}) cost of care seeking for children with MDP (SD)	1.11 (0.09)	1.14 (0.14)	0.03
Cluster mean % care seeking to an CHW for children with MDP (SD)	22.5% (23.03)	22.8% (16.92)	0.26
Cluster mean % care seeking to a public facility for children with MDP (SD)	50.96% (21.63)	48.79% (14.80)	2.17
Cluster mean CHW motivation score (SD)	2.29 (0.46)	2.38 (0.50)	0.09

162 *Outcomes are presented as mean percentages or mean costs across all clusters in each arm

163

164 Intervention coverage, sickness and care seeking

- By the end of the 18-month implementation period, 68% of CHWs reported having a working inSCALE phone and
- app, and 45% had sent a report via the app in the last 4 weeks (Table 3). Whilst overall prevalence of MDP was
- similar between arms at baseline, there were significant reductions in the prevalence of suspected malaria,
- 168 diarrhoea and pneumonia (reductions ranging from 18% to 45%), and a 16% increase in the prevalence of diagnostic
- 169 testing for malaria in the intervention arm at endline (Table 4). Care seeking to the CHW as the first port of call was
- 170 14.4% in the control arm and 15.9% in the intervention arm (199/1251). After accounting for the restricted
- 171 randomisation and clustered design this represented a 63% increase in care-seeking to the CHW, a result that just
- 172 fell short of significance (Table 5, p=0.085). There were no significant differences in care seeking rates to other
- 173 providers or in the prevalence of children for whom no care was sought (Table 5).

174 **Table 3.** Exposure to intervention components recorded during the endline survey

Intervention component	Technology
CHWs	N=104
% CHWs had a working phone and inSCALE app at endline (n)	68% (69)*
% CHWs submitted at least one inSCALE report through their phone in the last 4 weeks	45.2% (44)*

175 *data missing for 3 CHWs

176

177	Table 4. Prevalence of suspected malaria, diarrhoea and pneumonia (MDP) and blood tests for malaria in children under 5 years at baseline and endline
-----	---

Prevalence of			Endline (reported prevalence in last	Impact of inSCALE at endline	
	Control arm	Technology arm	Control arm	Technology arm	Risk ratio inSCALE/control RR: 95% CI; p*
Any of MDP	29.3% (662/2257)	30.4% (658/2165)	53.5% (1467/2740)	43.7% (1251/2863)	0.82 (0.78-0.87) p<0.001
Suspected malaria*	25.9% (562/2171)	26.7% (556/2084)	48.5% (1300/2682)	39.8% (1118/2808)	0.80 (0.72-0.89) p<0.001
Blood test for malaria**	31.7% (200/631)	29.5% (181/613)	59.7% (937/1570)	62.3% (831/1335)	1.16 (1.06-1.28) p=0.002
Confirmed malaria***	65.5% (131/200)	68.5% (124/181)	70.5% (661/937)	73.7% (612/831)	1.04 (0.92-1.18) p=0.514
Diarrhoea	5.1% (116/2257)	5.3% (114/2165)	7.2% (198/2740)	4.2% (121/2863)	0.55 (0.42-0.71) p<0.001
Pneumonia	9.9% (223)	11.8% (256/2165)	16.2% (443/2740)	10.6% (304/2863)	0.66 (0.44-0.99) p=0.045

178 Prevalence (n/N) calculated as total eligible children 2 months-59 months of age (N) with condition in question (n), with the exception of fever and malaria where age range is 4 months-59 months in line with treatment guidelines.

179 *Fevers, excludes fevers with a negative blood test for malaria. **denominator includes all children reporting fever in the last two (baseline) or 4 (endline) weeks. ***percentage of all blood tested fevers that were positive. *Adjusted for

180 i) parameters used to balance arms at baseline and ii) the baseline prevalence of prevalence parameter

181

182 Table 5. Care seeking choices for children with MDP at endline

Outcome % of children (n)	Control (N=1467)	Technology (N=1251)	Risk ratio tech/control RR: 95% Cl	р
% seeking care at a CHW (first point of call)	14.4% (211)	15.9% (199)	1.63 (0.93-2.85)	0.085
% seeking care at a CHW (at any point)	14.7% (215)	16.2% (203)	1.61 (0.91-2.85)	0.104
% Not seeking care outside the home	18.3% (269)	20.6% (251)	0.98 (0.74-1.30)	0.898
% seeking care at a public facility (at any point)	67.4% (988)	63.7% (797)	1.11 (0.93-1.33)	0.253
% seeking care in the private sector (at any point - private facility, pharmacy, shop, herbalist etc)	3.6% (53)	2.4% (30)	0.94 (0.51-1.71)	0.839

184 Appropriate Treatment

- Baseline levels of appropriate treatment were similar for the combined MDP endpoint but varied by provider and for 185 individual conditions between intervention arms (Table 6b). At endline there was an 26% increase in appropriate 186 treatment of cases of MDP (the primary outcome (Table 6a) in the inSCALE arm compared to the control arm (95% 187 confidence interval: 12%-42%, p<0.001). This rose to 30% when only episodes treated with recommended first line 188 189 treatments were defined as appropriately treated (Table 6a 95% CI: 12%-52%, p=0.001). A breakdown of appropriate treatment by provider suggests this impact was driven by significant improvements in appropriate 190 treatment coverage in public health facilities (Table 6a) which were the first port of call for caregivers for more than 191 192 60% of sick children in both arms (Table 5), and in the appropriate treatment of diarrhoea, where a 76% increase (95% CI 20%-256% p=0.003) in the use of oral rehydration salts was observed in the intervention arm (Table 7). Note 193 it was not possible to estimate a confidence interval for use of ORS plus zinc due to small cell sizes. Additional 194
- 195 improvements came in the use of the recommended first line antibiotic for pneumonia (50% increase in prescribing
- 196 of amoxicillin in the intervention arm 95% CI: 3%-217%). A whole-child analysis (Supplementary File 1 Table S6)
- 197 estimated an improvement of 40% in the proportion of children appropriately treated for all MDP condition(s)
- reported in the last 4 weeks in the intervention arm (95% CI: 9% 79% p=0.009).

	Control		Technology		Technology v Control**	
Appropriate treatment	%	n/N*	%	n/N*	RR (95% CI)	р
Any episode of MDP	47.8%	928/1941	50.7%	782/1543	1.26 (1.12-1.42)	<0.001
Any episode of MDP (first line treatments only)***	42.2%	819/1941	48.2%	744/1543	1.30 (1.12-1.52)	0.001
Appropriate treatment by first care seeking location (any episode of MDP)						
СНЖ	49.5%	146/ 295	61.9%	148/239	1.04 (0.86-1.25)	0.675
Public Facility	58.0%	736/1269	62.2%	594/955	1.26 (1.07-1.48)	0.004
Private sector (private facility, pharmacy, shop, herbalist)	29.4%	10/34	21.7%	5/23	1.66 (0.52-5.34)	0.392
No care seeking outside of the home	10.5%	36/343	10.7%	35/326	1.23 (0.75-2.00)	0.408

Table 6a. Appropriate treatment: Appropriate treatment of episodes suspected malaria, diarrhoea or suspected pneumonia (MDP)

201 *N=total episodes of the described disease; n=total episodes where the correct drugs were received

**adjusted for baseline levels of appropriate treatment for the condition(s) in question, and for variables used to balance arms at baseline (rates of facility and CHW care seeking, cost of care seeking, and CHW
 motivation score)

204 *** First line treatments: artemisinin combination therapy for malaria, ORS for diarrhoea, and amoxicillin for pneumonia

Table 6b. Primary Outcome at baseline: Percentage of episodes of MDP appropriately treated

	Control	Technology
Outcome	% (n/N*)	% (n/N*)
Total children in baseline sample	2257	2165
% children with MDP**	29.3% (662/2257)	30.4% (658/2165)
Appropriate treatment		
Any episode of MDP	33.1% (298/901)	28.2% (261/926)
Suspected malaria	31.3% (176/562)	28.4% (158/556)
Confirmed malaria	90.1% (118/131)	88.7% (110/124)
Diarrhoea (ORS)	56.0% (65/116)	44.7% (51/114)
Diarrhoea (ORS and zinc)	2.6% (3/116)	2.6% (3/114)
Pneumonia (any antibiotic)	25.6% (57/223)	20.3% (52/256)
Pneumonia (amoxicillin)	10.3% (23/223)	10.6% (27/256)
Any episode of MDP at the CHW (first care seeking location)	35.7% (71/199)	32.0% (70/219)
Any episode of MDP at the Public Facility (first care seeking location)	46.8% (214/457)	38.1% (171/449)
Any episode of MDP at the Private sector (first care seeking location, includes private facility, pharmacy, shop, herbalist)	18.8% (3/16)	19.2% (5/26)
Any episode of MDP - no care seeking outside of the home	10.1% (22/209)	6.2% (14/226)

*N=total episodes of the described disease; n=total episodes where the correct drugs were received. **MDP: denominator includes all children with suspected or confirmed malaria, diarrhoea or pneumonia

Table 7. Impact of the inSCALE intervention on appropriate treatment by condition

Outcome	Control arm	Technology arm			
	Freq (%)	Freq (%)	risk ratio versus control (95% CI)	р	
Appropriate treatment by condition					
Suspected malaria	54.4% (707/1300)	56.6% (633/1118)	1.08 (0.97-1.20)	0.150	
Confirmed malaria	96.4% (637/661)	96.2% (589/612)	1.02 (0.99-1.04)	0.221	
Diarrhoea (ORS)	29.3% (58/198)	43.8% (53/121)	1.76 (1.20-2.56)	0.003	
Diarrhoea (ORS + zinc)	0.0% (0/198)	1.7% (2/121)	-	-	
Suspected pneumonia (any antibiotic)	36.8% (163/443)	31.6% (96/304)	0.80 (0.60-1.08)	0.142	
Suspected pneumonia (amoxycillin)	12.2% (54/443)	19.1% (58/304)	1.50 (1.03-2.17)	0.033	

218 CHW motivation, identification, clinical knowledge, attrition, and stockouts

219 The mean motivation and the mean social identification scores were relatively high and did not differ between arms

220 (difference in motivation factors score: -0.03 95% CI -0.57, 0.51; difference in identification factor score: 0.01 95% CI

-0.42, 0.43). CHW attrition rates were approximately 18%-19% in both intervention arms with no detected difference

- 222 (Table 8). Overall scores for CHW clinical knowledge of the signs and management of MDP, also did not differ
- 223 significantly between arms (Table 8). A breakdown of CHW knowledge scores by condition suggests a trend of
- improved knowledge in technology arm CHWs particularly in diagnosing pneumonia and diarrhoea though none
- reached the threshold for statistical significance and may be chance findings (Table S3 in supplementary file 1).
- 226 There were no between-arm differences in the rate of stockouts for key MDP treatments in the previous 3 months,
- though overall rates of stockouts were fairly high at >50% (Table 8).
- 228
- Table 8. Community health worker (CHW) outcomes: Stockouts, attrition, motivation and knowledge in control and intervention
 arm clusters

Outcome	Control arm (N = 103)	Technology arm (N = 104)	Effect size (95% CI)	p	
	Mean (sd)	Mean (sd)			
% CHWs experienced a stockout of any MDP drug in last 3 months*	52.4% (54)	56.7% (59)	RR: 1.17 (0.92-1.49	0.207	
Mean CHW motivation score	4.6 (0.5)	4.7 (0.5)	RD: -0.03 (-0.57, 0.51)	0.914	
Mean CHW social identification score	4.7 (0.6)	4.8 (0.5)	RD: 0.01 (-0.42, 0.43)	0.976	
Mean CHW knowledge score	19.7 (4.3)	19.8 (4.4)	RD: 0.97 (-2.01, 3.94)	0.524	
Proportion CHW attrition (%)	18.4% (13.6)	18.5% (10.0)	RD: 1.31 (-18.66, 21.30)	0.878	

* Stockouts of any of artemisinin combination therapy, amoxycillin, or ORS. RR- risk ratio; RD- risk difference

232 Sensitivity analyses and robustness tests


- Sensitivity tests were conducted with two alternative definitions of appropriate treatment: i) only including children 233 with a positive malaria diagnostic test, and ii) including guinine as an appropriate treatment for malaria to account 234 for its use as a second line treatment or during in-patient care (S2 Table in the in Supplementary File 1). Both showed 235 a trend of improved coverage of overall appropriate treatment (20% an 14% improvement, p values 0.006 and 0.073 236 respectively for i) and ii)). We performed robustness tests of the key primary and secondary impact outcomes 237 appropriate treatment, care seeking, CHW motivation, social identity, clinical knowledge, stockouts, and attrition by 238 repeating the analyses using a comparison of cluster-level mean outcomes (S4 Table in Supplementary File 1). This 239 approach estimated similar significant improvements in appropriate treatment as the random effects model with the 240 exception of the increase in care seeking to CHWs which did not reach significance. 241
- 242
- 243

245 Meta-analysis of appropriate treatment for MDP: Uganda and Mozambique

- 246 Figure 2 shows the results of a fixed effects meta-analysis of the risk ratios (RRs) for percentage coverage of
- 247 appropriate treatment in Uganda and Mozambique. The analysis suggests implementation of the inSCALE technology
- 248 model could improve appropriate treatment by 15% (8% 24%) overall.

Figure 1. Flow diagram of participant progression through trial phases. Final analysis sample: children aged 2 months to 5 years with suspected malaria, diarrhoea or


251 suspected pneumonia (MDP). * Maxixe and Inhambane, the economic and provincial capitals were excluded from the study (do not implement iCCM).




255

256

Figure 2. Forest plot displaying an inverse-variance weighted fixed-effect meta-analysis of the effect of the inSCALE technology interventions on appropriate treatment of episodes of suspected malaria, diarrhoea or suspected pneumonia (Uganda and Mozambique). Effect size (ES) is the risk ratio for appropriate treatment.





baseline-adjusted risk ratio (effect size) of % episodes MDP appropriately treated in intervention versus control arm.

277 **Discussion**

278

We have demonstrated that a scalable, innovative technology-based intervention implemented in Mozambique can 279 meaningfully improve the coverage of appropriate treatment for common childhood illnesses covered by the iCCM 280 281 programme by 26-30%. We further showed in a meta-analysis of two countries (Mozambique and Uganda) implementing similar technology-based interventions that an 8-24% improvement in appropriate treatment is likely 282 achievable elsewhere. Our results suggest that iCCM programmes can contribute to the quality of care provided by 283 primary health services by the use of relatively inexpensive technology that prioritises support, efficiency and 284 285 performance. As a result of this work, the government of Mozambique has expanded the inSCALE technology 286 intervention to seven out of eleven provinces with over 2,500 CHWs and 299 supervisors using the app to date. The 287 programme will be rolled out to all 8,800 CHWs and 1,300 supervisors nationally by end of 2022 and a full data 288 integration plan with DHIS2 is ongoing to optimize strategic decision making(16,17). The expanded programme 289 name, upSCALE, reflects the successful and rapid uptake of our research into national policy and the creation of a national CHW mHealth system(17). 290

291 Our conceptual framework for the design of the inSCALE innovation expected that differences in CHW motivation, attrition and social identification would be one of the drivers of improvement in appropriate treatment(15,18). As 292 noted in our formative research and in other settings, ownership of local programmes can be fragmented, CHW 293 294 interventions are often only tenuously linked with the wider health system and therefore poorly supervised, and 295 their contribution under-recognised(19). The CHWs we surveyed however were in general highly motivated and 296 reported a strong degree of connectedness to the wider health system in both arms at baseline and at the end of follow-up. Local facility records estimated CHW attrition was moderate at 18% over the implementation period and 297 did not differ by intervention arm. Our findings suggest that in contrast to our conceptual framework, alternative 298 299 routes to impact may be more important in this setting. Though coverage of appropriate treatment in children taken 300 to the CHW was similar across arms, we observed the largest overall increase in coverage of appropriate treatment 301 occurred at public health facilities and in children with diarrhoea, very similar to the pattern of impact observed in 302 the sister inSCALE trial in Uganda [ref]. That these patterns were largely consistent across two countries with separate intervention design and implementation teams is a persuasive indicator of the alternative impact pathways 303 304 and mechanisms of impact through which inSCALE operates - and warrants further exploration in future studies. This nonetheless likely highlights the integrated nature of inSCALE intervention whereby training and usage of the app by 305 both CHWs and supervising staff at primary care facilities will have increased health worker exposure to guideline-306 307 led recommendations for disease management, alerts for low CHW stock for key commodities, motivational messaging, and reporting on prevalence of key childhood conditions. Diarrhoea in particular is often perceived 308 simply as a symptom of a more highly prioritised condition on which treatment is focused(20) and may therefore be 309 overlooked by health workers even if ORS is available (20–22). These findings point to the gains that may be made by 310 adopting an approach that not only strengthens community based iCCM programmes, but the linked primary health 311 care system. 312

Coverage of the inSCALE innovation after 18 months of follow-up was moderate to good (68% CHWs had a working 313 phone and inSCALE app and 45% had sent a report in the last month). It is difficult to assess this intervention 314 coverage rate in context of similar interventions due to the variability in intervention components, and in endpoint 315 definitions. A SMS (short message service) message-based randomised controlled trial in Tanzania delivered 7 316 317 messages to drug shop vendors with recommendations for correct treatment of malaria and reported 70% of dispensers received at least 75% of the intended SMS messages. Whilst this appears comparable to our reported 318 319 rates, the difference in the health provider type and in the content of the intervention precludes a direct comparison 320 (23). Nonetheless a review of a selection of trials of child health-based mHealth interventions in low and middle income country settings (LMICs) report widely varying intervention coverage rates between 24% and 85% (24,25). 321 Lack of medicinal stock for common childhood conditions has been a barrier to prompt and appropriate treatment in 322 other settings(26), and affected our study sites in Mozambique during and after the period of implementation (8,19). 323 Key issues were the national stock outs of key malaria and antibiotic medications and diagnostic tests within the last 324 325 6 months of the study, which may have supressed the full potential impact of the technology intervention for these outcomes. Research by Save the Children in this setting suggests that households who were aware of stockouts at 326 the iCCM CHW may go elsewhere for treatment(19). More than 50% of CHWs across both arms reporting at least 327 328 one stockout of supplies for the management of MDP in the previous 3 months; such commodity supply barriers 329 were outside the control of our intervention nonetheless it was encouraging that our results highlight a positive 330 impact of the inSCALE app in maintaining or improving overall coverage of clinical management for pneumonia and diarrhoea despite these persistent issues and moderate intervention coverage. 331

332

333 Wider implications on case prevalence, fatality, productivity, user costs and transmission

The highest case fatality rates for pneumonia, malaria and diarrhoea occur in sub-Saharan Africa(27,28) Separate 334 335 cost-effectiveness studies for the inSCALE trials in Uganda and Mozambique [ref] estimate that increasing coverage of appropriate treatment will have a modest impact on child deaths (1-5%). However important proximal outcomes 336 337 of such interventions include a potential to reduce community transmission of causative pathogens and/or the risk 338 of recurrent MDP infections (29) and lowering cost of care seeking and increasing equitable access to care (22) through the strengthening and raised profile of iCCM-trained CHWs. Reduced community transmission in particular 339 was suggested by the decrease in prevalence of MDP both over time across the study site in Mozambique, and the 340 additional significantly faster fall prevalence in the intervention arm districts. There is a plausible route to this effect 341 through the increase in the timely use of medications, and/or in awareness of preventative measures (30,31). The 342 343 reduction in disease prevalence, and improvement in appropriate treatment for diarrhoea and pneumonia are particularly to be welcomed considering no single preventative intervention may be easily applied to control these 344 diseases as a result of their multiple pathogen aetiology(32). 345

Our study had several limitations. Our estimates of prevalence of MDP and appropriate treatment were based on caregiver reports which may be subject to misclassification. Studies of caregiver recall for pneumonia and malaria symptoms have sensitivities and specificities in the range of 31%-91% depending on the setting(33,34).

349 Recommended strategies to improve the accuracy of disease and treatment estimates include setting the length of the recall period to four weeks (versus 2 weeks used in the inSCALE baseline survey), the use of pictures of available 350 treatments to respondents and the development of survey questions which prioritise local terms and are based on 351 well-validated survey instruments(33–35) including the United Nations- and USAID-supported Multiple Indicator 352 353 Cluster Survey and Demographic Health Surveys (36,37). We incorporated all these strategies in our surveys and used tailored definitions of disease and treatments in line with national guidelines, including the presumptive use of 354 ACT to treat fever, a practice compounded by nationwide stockouts of iCCM drugs and tests at the time. Our 355 356 sensitivity analyses of the main outcome with alternative definitions of appropriate treatment [see Table supplementary file 1] nonetheless produced similar results – of note, restricting cases of fever to those with a 357 confirmed malaria test estimated a 20% improvement in appropriate treatment which remained highly significant. 358 359 The inSCALE study evaluated the impact of strategies to improve scale-up and coverage of iCCM programmes using a randomised controlled design as we believed this method would provide the most convincing effectiveness 360 361 estimates for stakeholders. The number of district clusters available for randomisation was however determined by iCCM programme readiness (iCCM-trained CHWs in place) and lack of concurrent interventions in the area at 362 baseline. This resulted in twelve districts available for randomisation. We tested the robustness of our random-363 364 effects models with cluster-averaged t-tests of our primary outcomes as recommended by Hayes and Moulton(38), 365 and whilst less powerful, we observed similar estimates of impact on appropriate treatment (See supplementary file

366 1).

367 Conclusions

The body of research evidence for digital and mHealth programmes is increasing, however there remains a 368 significant gap for evidence from good quality studies of the potential for available and emerging technologies to 369 transform health outcome in LMICs for children, particularly when delivered via community-based health worker 370 371 cadres(39). Mobile phone penetration is predicted to increase in sub-Saharan Africa(40) and is estimated to be a key 372 medium by which health care access and service delivery can be improved for the underserved. The WHO's recently published set of global recommendations for digital interventions for health services delivery highlight the potential 373 374 of mHealth interventions for a range of uses and includes the key components of the inSCALE technology intervention – clinical decision support, stock tracking and provider-to-provider telemedicine (41). Significantly, the 375 2019 WHO/UNICEF iCCM strategy meeting in Addis Ababa recommended "Interventions to improve quality, 376 including supportive supervision and mentoring of CHWs in designated health facilities, are essential to ensure high-377 quality iCCM and should be budgeted for and included in district plans" (42). This renewed encouragement for 378 implementation of iCCM this decade may encourage relevant stakeholders looking to efficiently scale up 379 programmes to explore digital solutions for their context. Our study and meta-analysis together with the expansion 380 of the inSCALE programme in Mozambique (16,17) highlight the potential scalability of an mHealth intervention 381 aimed at strengthening iCCM systems to address the largest causes of childhood morbidity and mortality in sub-382 Saharan Africa. 383

385 Materials and Methods

386 Study Site

The study took place in the Inhambane Province of southern Mozambique between November 2013 and July 2016. 387 The province covers a geographical area of 68,775km² with a population of approximately 1.4 million of which 17% 388 389 are under 5 years of age(43). The Inhambane mortality rate in this age group at the start of the study was 76.4 deaths per 1000 livebirths(44), with more than 60% of all deaths in the province caused by a combination of malaria, 390 391 diarrhoeal diseases and pneumonia(45,46). Sine 2011, iCCM had been included in the Inhambane programme of work for Agentes Polivalentes Elementares (APE), the name for the local cadre of community health worker and 392 referred to as CHWs in this paper. Government and donor funding for the programme supported the training, 393 394 supervision and provision of iCCM commodities for all CHWs in the province throughout the study period. A detailed study protocol for the inSCALE trial in Mozambique has been published elsewhere(15). Details of the setting and 395 396 study design for the inSCALE study in Uganda, used for the metanalysis presented in this paper, is published elsewhere [ref]. 397

398 Study Design and Participants

We conducted a superiority open label two-arm cluster-randomised controlled trial in 12 districts in Inhambane 399 Province in southern Mozambigue. Six districts (Funhalouro, Govuro, Jangamo, Panda, Vilankulo, and Zavala) were 400 randomised to the inSCALE intervention and six (Homoine, Inharrime, Inhassouro, Mabote, Massinga, and 401 Morrumbene) to the control arm. The provincial and economic capitals of Inhambane, Inhambane and Maxixe 402 403 respectively, was excluded from the randomisation and Maxixe was instead used for piloting of the intervention in its rural areas during the design stage. Intervention allocation was randomised at the district level as this was the 404 lowest unit of administration and training for the CHW iCCM programme and therefore for implementation of the 405 406 inSCALE intervention. Eligible households within the district were defined as those with at least one resident child under five years of age at any point during the study in a community served by at least one iCCM-trained CHW. Local 407 data collected by Malaria Consortium in the area in 2011 suggested that 45% of households within each community 408 fit the eligibility criteria. 409

Ethical approval for the study was obtained from the Mozambigue National Bioethics Committee for Health 410 (reference 345-CNBS-10) and the London School of Hygiene & Tropical Medicine Ethics Committee in the UK 411 (reference 5762). Approval for the random allocation of districts to intervention or control groups and 412 implementation of the interventions was obtained from the Inhambane Provincial Office responsible for health 413 administration for the province. Written informed consent was obtained from the main caregiver of each child under 414 5 years of age for baseline and follow up data collection. Consent forms included an explanation of the purpose of 415 416 the data collection and confirmed participants were free to withdraw at any time. The inSCALE trial is registered on clinicaltrials.gov with identifier NCT01972321. 417

419 Randomisation and Blinding

In order to reduce the likelihood of chance imbalances between intervention arms at baseline given the number of 420 clusters available for randomisation(38,47)., we performed a randomisation that was restricted with respect to the 421 percentages of households with sick children seeking care at a public health facility, the percentage seeking care to a 422 CHW, average CHW motivation (composite) score and the log cost of care seeking for sick children. Data for these 423 424 parameters was obtained from a baseline survey conducted between November- December 2012. We used the statistical software Stata (version 13) to generate the 924 possible randomisation schemes for the 12 districts and 425 picked one at random from the subsection of 84 schemes that fitted our balance criteria(48) [see online supplement 426 427 file 1]. Due to the nature of the technology intervention, it was not possible to blind participants or fieldworkers to the intervention allocation, however allocation was masked in the database and all analyses were initially performed 428 on data with intervention allocation removed and repeated on unblinded data after agreement on the final analysis 429 methods with study partners. 430

431 Study Procedures – data collection

The baseline survey was conducted in all households in 2-8 randomly-selected communities (known as enumeration areas or EAs) sampled proportional to size in each district in order to cover approximately 500 households per district (mean of 91 households per village), which would provide 80-90% power to detect an impact of the intervention in accordance with the estimated sample sizes for detecting intervention impact at endline as described in the inSCALE protocol paper(15). Approximately 21 CHWs were also surveyed per district at baseline (1-2 per village). Community sampling frame data were based on complete enumeration information provided by the District Offices and EA location, size and households were verified by field workers.

The baseline survey was administered to caregivers of children under 5 years of age, and collected information on 439 symptoms of malaria, diarrhoea, and pneumonia (MDP) in these children in the last 4 weeks, care seeking for these 440 illnesses, costs of care, socioeconomic data at the household level. Household guestionnaires were based on 441 standard health survey instruments used in the country (Mozambigue DHS(36) and Malaria Indicator Cluster 442 443 Surveys(37)). The CHW survey included data on CHWs' clinical knowledge, time use, motivation and 'social identity' – 444 or sense and degree of connectedness to the local and national CHW and health services systems. The CHW clinical knowledge instrument was developed based on the format and example clinical event scenarios in the WHO Health 445 446 Facility Survey Tool template (49). The likert scale-based CHW motivation and identity tool used a pictorial scale indicating degree of agreement with statements about enthusiasm for the job, motivation and identification with the 447 448 local and national iCCM programme, and was developed based on extensive formative research by the study team 449 on health worker motivation and social identity (50,51). Both tools were adapted to the Mozambique setting prior to usage with the input of facility staff and CHWs in an iterative process that developed wording, accompanying 450 451 graphics and reference to local health system structures and clinical guidelines.

Household and CHW surveys were also extensively field piloted with field staff including workshops role playing and
 refining of translations, and all tools were delivered in Portuguese. A quality control check of 10% of the weekly

survey households was undertaken by field worker supervisors. Pictures of locally available medications were used in
the household surveys to improve the accuracy of reports of treatment for MDP(33).

At the end of the follow-up period an endline impact survey was conducted in May-June 2015 in the same villages visited at baseline in households with children meeting inclusion criteria at endline, and again covering all active CHWs serving the selected villages. The survey collected data across the same themes to estimate study impact and included additional questions to CHWs and caregivers on coverage of the inSCALE innovation components in the

460 intervention arm. All household and CHW data collection tools are available in Supplementary File 2.

461 Intervention

The inSCALE technology intervention was developed in collaboration with Dimagi a social enterprise corporation 462 focused on the development of digital solutions for health workers in low and middle income settings (52). Steering 463 and input was received from the Mozambique ministry of health, community and facility-based stakeholders, 464 465 funding bodies and the inSCALE trial steering committee(15,53). The aim of the innovation was to leverage technological strategies to strengthen links between fragmented CHW programmes and the primary care health 466 services including links between CHW peers and health facility staff, and by doing so to improve CHW outcomes and 467 468 child health outcomes for children. The inSCALE technology intervention development process and conceptual framework linking intervention components, outputs and outcomes is described in detail in the protocol paper (15). 469 The technology intervention was implemented in July 2013, and after a 6 month roll-out and embedding period, 470 follow-up to impact analysis continued to July 2015 (18 months). iCCM-trained CHWs and their health facility 471 supervisors in the intervention arm were provided with a Samsung[®] smartphone installed with the inSCALE mHealth 472 473 application, a solar charger with a number of pin adapters, and a solar lamp for night-time consultations. Intervention arm CHWs and health facility supervising staff were trained in the use of the mHealth tools. Training 474 was conducted using a cascade approach where 7 master trainers trained 18 facility- and community-based trainers 475 476 who in turn trained 47 health facility supervisors and 132 CHWs in the technology arm over 4 days with follow-up support provided by the project team during the implementation period. The inSCALE mHealth mobile app 477 478 consisted of a sick child decision support algorithm in a user-friendly interface including multimedia, audio and images to improve adherence to iCCM treatment protocols. CHWs were additionally able to use the phones to track 479 consultations with sick children, make diagnoses and management choices, report key statistics to a central server, 480 481 request stock from their supervising facilities, and maintain a register of patients seen. These reports were forwarded on a weekly basis to health facility supervising staff who received tailored follow-up supervision prompts. 482 The inSCALE app also worked offline, therefore where there were network coverage issues, CHWs and health facility 483 484 supervising staff had the option to delay sending of reports until they were in a location with better coverage. CHWs and supervisors were allocated to local closed user groups which enabled complimentary calls with the inSCALE 485 smartphones to be made without charge to fellow members in the group. Finally, CHWs and their health facility 486 supervisors received weekly (CHWs only) and monthly (CHWs and facility supervisors) automated motivational 487 messages tailored to their report results with the tone and emphasis based on formative work. After an initial 6-488 489 month roll-out and embedding phase, the technology intervention continued to be implemented in intervention arm

districts for an additional 18 months. Standard care during this period was available in both intervention and control
 arm districts, where CHWs and health facilities provided guideline-led management for childhood illnesses via the
 underlying iCCM programme and integrated management of neonatal and childhood illnesses (IMNCI) services(9,54)
 respectively.

Data on CHW recruitment, training, resignations, and replacements were tracked by supervising health facilities at
 district level and this data was regularly extracted into the inSCALE database during the follow-up period by the
 study team in order to estimate attrition rates.

497

498 Outcomes

The primary outcome for the trial was the percentage of recent cases of MDP in the last 4 weeks in children 2 499 months to 5 years of age that were treated using appropriate medication(15). Secondary outcomes were the 500 501 prevalence of MDP in children at endline, the percentage of cases of MDP appropriately treated with recommended first line medications, the percentage of children who sought care for MDP by provider type, the percentage of 502 CHWs who had had a stock-out of iCCM medications in the past 3 months, CHW attrition rate calculated as the 503 504 proportion of CHWs who left their post during the follow-up period out of the total CHWs trained at baseline, CHW clinical knowledge scores (overall and by condition subgroup), and composite scores describing CHW enthusiasm and 505 drive for the job (motivation) and sense of connectedness to the local and national iCCM programme (social 506 identification). CHW knowledge scores were calculated as the sum of correct clinical decisions mentioned by the 507 CHW in response to a series of scenarios involving children with symptoms of mild and severe disease. Points for 508 509 correct items were weighted according to an algorithm defined in Supplementary file 1. CHW motivation and social 510 identification scores were calculated by a factor analysis and empirical item reduction process applied to original field tool responses. The methods have been detailed previously(55), and resulted in a three-factor CHW motivation 511 512 scale of 17 items measuring general motivation, feelings of reward for effort, and retention in role. An additional single factor CHW scale of 4 items was identified which explained the majority of the variation in social identification 513 514 between CHWs. Retained items from both the motivation and social identification tools showed good internal consistency (alpha = 0.67 for CHW motivation and alpha = 0.69 for CHW social identification). The final motivation 515 scores were calculated as the product of the rotated factor analysis regression coefficients and the Likert value for 516 517 each original item. The final social identification scores were calculated as the sum of the original 4 items (after reverse coding as appropriate). 518

Additional impact measures included the percentage of children who were appropriately treated overall whether they had symptoms of one or more of MDP in the last 4 weeks (i.e. a per-child analysis), and two sensitivity analyses of the main impact outcome using alternative definitions of appropriate treatment. All definitions of appropriate treatment and medications used in primary secondary and additional endpoints are provided in Supplementary File 1 (Table S8).

- 525
- 526

527 Statistical analysis

528 All analyses were based on intention-to-treat principles and accounted for the cluster-randomised design. Multivariate mixed-effects models were specified for all impact outcomes, which account for the clustering of 529 outcomes by inclusion of a random intercept at the district level. Intervention arm, the cluster mean percentage of 530 children who were appropriately treated at baseline, and the parameters used to balance intervention arms during 531 randomisation were included as fixed effects. Unadjusted analyses of impact were also performed, and the results 532 included in supplementary file 1 (Table S1). For the primary outcome and other binary models, odds ratios were 533 converted to risk ratios using the marginal standardisation technique and 95% CIs estimated using the delta method 534 (56). Additional sensitivity analyses of the primary outcome were conducted to account for alternative treatments 535 536 available for MDP [see Supplementary file 1 Table S8 for definitions]. Robustness checks of the primary outcomes were conducted by estimating cluster averaged results using t-tests following the procedures of Haves and 537 Moulton(38), recommended when the number of clusters per arm is less than 10(38) [see Supplementary file 1]. 538 539 CHW attrition was estimated using cluster-averaged mean rates as human resources information was provided at this level only from district health offices. In order to estimate a pooled effect of the inSCALE technology 540 intervention on appropriate treatment across both Uganda and Mozambique, we performed a meta-analysis of 541 effect sizes by combining the results of the Mozambique (this study) and Uganda [ref] trials of the inSCALE 542 intervention. As there was no significant heterogeneity (<50% estimated from exploratory meta-analysis models) 543 544 between studies, we present the pooled result from a fixed effects meta-analysis.

546

548 Supplementary file Tables

Table	Caption
Supplementary file 1	
S1	Unadjusted analyses of primary outcomes
	Sensitivity analyses for primary outcome at endline (any
	episode of MDP): Alternative definitions of appropriate
S2	malaria treatment
S3	Whole Child Analysis – Appropriate treatment
	Robustness tests (cluster-averaged outcomes) – Primary
S4a	Outcomes
	Robustness tests (cluster-averaged outcomes) – Secondary
	Outcomes: appropriate treatment stratified by condition or
S4b	provider
	Robustness tests (cluster-averaged outcomes) – Secondary
	outcomes: prevalence of suspected and confirmed malaria,
S5	malaria blood testing, diarrhoea, and pneumonia
	CHW clinical knowledge by subgroup (diagnosis of MDP,
S6	treatment of MDP)
S7a	Item weighting – Case study: Francis/Alberte (pneumonia
	and diarrhoea)
S7b	Item weighting – Case study: Hope/Tina (malaria)
S7c	Item weighting – Case study: Beatrice/Janete (severe
	pneumonia)
S7d	Item weighting – Case study: Muteesa/Kizito (severe
	disease/malaria)
S7e	Item weighting – Case study: James (severe disease/malaria)
S7f	CHW Knowledge scoring for subcategories: diagnosis and
	treatment of suspected malaria, diarrhoea and pneumonia
S8	Definitions of appropriate treatment and other key child
	health outcomes
Supplementary file 2	
inSCALE data collection	n forms

549

551

552 References

- WHO. Children: improving survival and well-being [Internet]. 2020 [cited 2021 Sep 29]. Available from: https://www.who.int/news-room/fact-sheets/detail/children-reducing-mortality
- UNICEF. Levels and trends in child mortality 2019: Estimates developed by the UN Inter-agency group for child
 mortality estimation [Internet]. 2019. Available from: https://www.unicef.org/reports/levels-and-trends-child mortality-report-2019
- WHO, UNICEF. WHO/UNICEF JOINT STATEMENT: Integrated Community Case Management (iCCM) [Internet].
 2012 [cited 2021 Sep 22]. Available from: https://www.who.int/maternal child adolescent/documents/statement child services access whounicef.pdf
- 561 4. Kallander K, Burgess DH, Qazi SA. Early identification and treatment of pneumonia: a call to action. Lancet Glob 562 Health. 2016 Jan 1;4(1):e12–3.
- 5. Diaz T, Aboubaker S, Young M. Current scientific evidence for integrated community case management (iCCM) in Africa: Findings from the iCCM Evidence Symposium. J Glob Health. 2014 Dec;4(2):020101.
- Boschi-Pinto C, Labadie G, Dilip TR, Oliphant N, Dalglish SL, Aboubaker S, et al. Global implementation survey of
 Integrated Management of Childhood Illness (IMCI): 20 years on. BMJ Open. 2018 Jul 1;8(7):e019079.
- Allen KC, Whitfield K, Rabinovich R, Sadruddin S. The role of governance in implementing sustainable global
 health interventions: review of health system integration for integrated community case management (iCCM)
 of childhood illnesses. BMJ Glob Health. 2021 Mar 1;6(3):e003257.
- Prosnitz D, Herrera S, Coelho H, Moonzwe Davis L, Zalisk K, Yourkavitch J. Evidence of Impact: iCCM as a
 strategy to save lives of children under five. J Glob Health. 2019 Jun;9(1):010801.
- Oliphant NP, Manda S, Daniels K, Odendaal WA, Besada D, Kinney M, et al. Integrated community case
 management of childhood illness in low- and middle-income countries. Cochrane Database Syst Rev [Internet].
 2021 [cited 2021 Sep 22];(2). Available from:
- 575 https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012882.pub2/full
- The Global Fund for HIV TB and Malaria, WHO, UNICEF. Integrated Community Case Management (iCCM) in
 Sub-Saharan Africa: Successes & Challenges with Access, Speed & Quality [Internet]. Nairobi, Kenya; 2018 Aug
 [cited 2021 Sep 30] p. 145. Available from:
- 579 https://www.theglobalfund.org/media/9754/core_integratedcommunitycasemanagementsub-580 saharanafrica review en.pdf
- WHO Global Observatory for eHealth. mHealth: new horizons for health through mobile technologies: second
 global survey on eHealth. 2011 [cited 2022 Feb 5]; Available from:
 https://apps.who.int/iris/handle/10665/44607
- Braun R, Catalani C, Wimbush J, Israelski D. Community Health Workers and Mobile Technology: A Systematic
 Review of the Literature. Bullen C, editor. PLoS ONE. 2013 Jun 12;8(6):e65772.
- Källander K, Tibenderana JK, Akpogheneta OJ, Strachan DL, Hill Z, ten Asbroek AHA, et al. Mobile Health
 (mHealth) Approaches and Lessons for Increased Performance and Retention of Community Health Workers in
 Low- and Middle-Income Countries: A Review. J Med Internet Res. 2013 Jan 25;15(1):e17.
- World Bank. Mobile cellular subscriptions (per 100 people) Sub-Saharan Africa [Internet]. 2020 [cited 2022
 Feb 5]. Available from: https://data.worldbank.org/indicator/IT.CEL.SETS.P2?locations=ZG

591 Källander K, Strachan D, Soremekun S, Hill Z, Lingam R, Tibenderana J, et al. Evaluating the effect of innovative 15. motivation and supervision approaches on community health worker performance and retention in Uganda 592 593 and Mozambigue: study protocol for a randomised controlled trial. Trials. 2015 Apr 12;16(1):157. 594 16. Feldman M, Krylova VL, Farrow P, Donovan L, Zandamela E, Rebelo J, et al. Community health worker knowledge, attitudes and practices towards COVID-19: Learnings from an online cross-sectional survey using a 595 digital health platform, UpSCALE, in Mozambique. PLOS ONE. 2021 Feb 10;16(2):e0244924. 596 Malaria Consortium. upSCALE mHealth system strengthening for case management and disease surveillance. 597 17. 598 2018 [cited 2021 Sep 17]; Available from: https://www.malariaconsortium.org/upscale/ Global Fund to Fight AIDS, Tuberculosis and Malaria. Global Fund Thematic Review on Community Health 599 18. [Internet]. 2020 Jun [cited 2022 Feb 18] p. 46. Available from: 600 https://www.theglobalfund.org/media/10128/core endasantecommunityhealthsynthesis review en.pdf 601 Save the Children. Systems Effects of Integrated Community Case Management Projects: Mozambique Country 602 19. Report [Internet]. Resource Centre. 2019 [cited 2021 Jun 11]. Available from: 603 604 https://resourcecentre.savethechildren.net/library/systems-effects-integrated-community-case-management-605 projects-mozambique-country-report 606 20. Unger CC, Salam SS, Sarker MSA, Black R, Cravioto A, Arifeen SE. Treating diarrhoeal disease in children under five: the global picture. Arch Dis Child. 2014 Mar 1;99(3):273-8. 607 608 21. Nsabagasani X, Ogwal-Okeng J, Mbonye A, Ssengooba F, Muhumuza S, Hansen EH. Availability and utilization of the WHO recommended priority lifesaving medicines for under five-year old children in public health facilities 609 in Uganda: a cross-sectional survey. J Pharm Policy Pract. 2015 May 11;8(1):18. 610 Soremekun S, Kasteng F, Lingam R, Vassall A, Kertho E, Settumba S, et al. Variation in the quality and out-of-22. 611 pocket cost of treatment for childhood malaria, diarrhoea, and pneumonia: Community and facility based care 612 in rural Uganda. PLOS ONE. 2018 Nov 26;13(11):e0200543. 613 Bruxvoort K, Festo C, Kalolella A, Cairns M, Lyaruu P, Kenani M, et al. Cluster Randomized Trial of Text Message 614 23. Reminders to Retail Staff in Tanzanian Drug Shops Dispensing Artemether-Lumefantrine: Effect on Dispenser 615 616 Knowledge and Patient Adherence. Am J Trop Med Hyg. 2014 Oct 1;91(4):844-53. Zurovac D, Sudoi RK, Akhwale WS, Ndiritu M, Hamer DH, Rowe AK, et al. The effect of mobile phone text-617 24. 618 message reminders on Kenyan health workers' adherence to malaria treatment guidelines: a cluster randomised trial. Lancet Lond Engl. 2011 Aug 27;378(9793):795-803. 619 Friedman W, Woodman B, Chatterji M. Can mobile phone messages to drug sellers improve treatment of 620 25. childhood diarrhoea?--A randomized controlled trial in Ghana. Health Policy Plan. 2015 Mar;30 Suppl 1:i82-92. 621 Mubiru D, Byabasheija R, Bwanika JB, Meier JE, Magumba G, Kaggwa FM, et al. Evaluation of Integrated 622 26. Community Case Management in Eight Districts of Central Uganda. PLOS ONE. 2015 Aug 12;10(8):e0134767. 623 624 27. Marangu D, Zar HJ. Childhood pneumonia in low-and-middle-income countries: An update. Paediatr Respir Rev. 625 2019 Nov;32:3-9. WHO. Child mortality and causes of death [Internet]. Geneva, Switzerland; 2022 [cited 2022 Feb 18]. (Global 626 28. 627 Health Observatory). Available from: https://www.who.int/data/gho/data/themes/topics/topicdetails/GHO/child-mortality-and-causes-of-death 628 629 29. Information NC for B, Pike USNL of M 8600 R, MD B, Usa 20894. Malaria transmission and antimalarial medicines [Internet]. Guidelines for the Treatment of Malaria. 3rd edition. World Health Organization; 2015 630 [cited 2021 Sep 21]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK294437/ 631

- Lam F, Wentworth L, Cherutich P, Migiro S, Abdala K, Musyoka M, et al. An evaluation of a national oral
 rehydration solution and zinc scale-up program in Kenya between 2011 and 2016. J Glob Health. 9(1):010505.
- Nawa M. Investigating the Effect of Prompt Treatment on Malaria Prevalence in Children Aged below Five
 Years in Zambia: A Nested Case-Control Study in a Cross-Sectional Survey. Adv Public Health. 2020 Jan
 16;2020:e4289420.
- Gazi S, Aboubaker S, MacLean R, Fontaine O, Mantel C, Goodman T, et al. Ending preventable child deaths from
 pneumonia and diarrhoea by 2025. Development of the integrated Global Action Plan for the Prevention and
 Control of Pneumonia and Diarrhoea. Arch Dis Child. 2015 Feb 1;100(Suppl 1):S23–8.
- Campbell H, Arifeen S el, Hazir T, O'Kelly J, Bryce J, Rudan I, et al. Measuring Coverage in MNCH: Challenges in
 Monitoring the Proportion of Young Children with Pneumonia Who Receive Antibiotic Treatment. PLOS Med.
 2013 May 7;10(5):e1001421.
- 543 34. Eisele TP, Silumbe K, Yukich J, Hamainza B, Keating J, Bennett A, et al. Measuring coverage in MNCH: accuracy
 of measuring diagnosis and treatment of childhood malaria from household surveys in Zambia. PLoS Med.
 2013;10(5):e1001417.
- Walker CLF, Fontaine O, Black RE. Measuring Coverage in MNCH: Current Indicators for Measuring Coverage of
 Diarrhea Treatment Interventions and Opportunities for Improvement. PLOS Med. 2013 May
 7;10(5):e1001385.
- 36. Demographic Health Surveys. The DHS Program Questionnaires and Manuals [Internet]. USAID. [cited 2021
 Jun 11]. Available from: https://dhsprogram.com/Methodology/Questionnaires.cfm
- 651 37. UNICEF. Tools UNICEF MICS [Internet]. [cited 2021 Jun 11]. Available from: https://mics.unicef.org/tools
- 38. Hayes R, Moulton L. Cluster Randomised Trials [Internet]. 2nd ed. Chapman and Hall/CRC; [cited 2021 Jun 10].
 Available from: https://www.routledge.com/Cluster-Randomised-Trials/HayesMoulton/p/book/9781498728225
- 655 39. Feroz A, Jabeen R, Saleem S. Using mobile phones to improve community health workers performance in low-656 and-middle-income countries. BMC Public Health. 2020 Jan 13;20(1):49.
- 40. Crul S, Diop J. The mHealth opportunity in Sub-Sahara Africa: The path towards practical application [Internet].
 Deloitte; 2014 [cited 2021 Sep 20]. Available from:
- 659 https://www2.deloitte.com/content/dam/Deloitte/nl/Documents/technology-media-
- 660 telecommunications/deloitte-nl-mhealth.pdf
- WHO. WHO Guideline: recommendations on digital interventions for health system strengthening [Internet].
 World Health Organization; 2019 [cited 2021 Sep 21]. Available from:
 http://www.who.int/reproductivehealth/publications/digital-interventions-health-system-strengthening/en/
- WHO, UNICEF. Institutionalising integrated community case management (iCCM) to end preventable child
 deaths: Technical consultation and country action planning 22-26 July 2019, Elilly International Hotel, Addis
 Ababa, Ethiopia.
- 43. National Institute of Statistics Mozambique. Inhambane Instituto Nacional de Estatistica [Internet]. 2013
 [cited 2021 Jun 11]. Available from: http://www.ine.gov.mz/estatisticas/estatisticas-territoriasdistritais/inhambane

670	44.	UN Inter-agency Group for Child Mortality Estimation. Under five Mortality Rate - Mozambique [Internet].
671		[cited 2021 Jun 11]. Available from: https://childmortality.org/data/Mozambique

- Fernandes QF, Wagenaar BH, Anselmi L, Pfeiffer J, Gloyd S, Sherr K. Effects of health-system strengthening on
 under-5, infant, and neonatal mortality: 11-year provincial-level time-series analyses in Mozambique. Lancet
 Glob Health. 2014 Aug;2(8):e468–77.
- 46. Källander K, Counihan H, Cerveau T, Mbofana F. Barriers on the pathway to survival for children dying from
 treatable illnesses in Inhambane province, Mozambique. J Glob Health [Internet]. [cited 2021 Jun 11];9(1).
 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6596358/
- 47. Ivers NM, Halperin IJ, Barnsley J, Grimshaw JM, Shah BR, Tu K, et al. Allocation techniques for balance at
 baseline in cluster randomized trials: a methodological review. Trials. 2012 Aug 1;13(1):120.
- 48. Moulton LH. Covariate-based constrained randomization of group-randomized trials. Clin Trials Lond Engl.
 2004;1(3):297–305.
- 49. WHO. Health facility survey : tool to evaluate the quality of care delivered to sick children attending outpatient
 facilities [Internet]. World Health Organization; 2003 [cited 2021 Jun 11]. Available from:
 https://apps.who.int/iris/handle/10665/42643
- 50. Chandler CIR, Chonya S, Mtei F, Reyburn H, Whitty CJM. Motivation, money and respect: a mixed-method study of Tanzanian non-physician clinicians. Soc Sci Med 1982. 2009 Jun;68(11):2078–88.
- 51. Franco LM, Bennett S, Kanfer R, Stubblebine P. Determinants and consequences of health worker motivation in
 hospitals in Jordan and Georgia. Soc Sci Med 1982. 2004 Jan;58(2):343–55.
- 52. DIMAGI. Dimagi | Technology for Social Impact [Internet]. Dimagi. [cited 2022 May 9]. Available from:
 https://www.dimagi.com/
- 53. Strachan DL, Källander K, Nakirunda M, Ndima S, Muiambo A, Hill Z, et al. Using theory and formative research
 to design interventions to improve community health worker motivation, retention and performance in
 Mozambique and Uganda. Hum Resour Health. 2015 Apr 30;13:25.
- 54. WHO, UNICEF, editors. Handbook IMCI: integrated management of childhood illness. Geneva: World Health
 Organization; 2005. 163 p. (IMCI, Integrated Management of Childhood Illness).
- 55. Strachan DL. Ugandan community health worker motivation: using the Social Identity Approach to explore an
 accepted constraint to scaled up health strategies [Internet] [Doctoral]. Doctoral thesis, UCL (University College
 London). UCL (University College London); 2019 [cited 2022 Feb 5]. p. 1–410. Available from:
 https://discovery.ucl.ac.uk/id/eprint/10073256/
- 56. Localio AR, Margolis DJ, Berlin JA. Relative risks and confidence intervals were easily computed indirectly from
 multivariable logistic regression. J Clin Epidemiol. 2007 Sep;60(9):874–82.
- 702

703 Contributors

- 704 SS, KK, RL, FK, ACB, AB, DS, ZH, GA, JT, NS, JC, FB, SM and BK designed and performed the study. SS analysed the
- data. SS, RL and KK drafted the manuscript and FK, ACB, AB, ZH, GA, JT, NS, JC, FB, SM and BK reviewed the
- 706 manuscript. KK, RL, FK, DS, ZH, JT provided critical comments on the review of the manuscript. All authors have read
- 707 and approved the final manuscript.

708 Declaration of Competing Interest

709 We declare no competing interests.

710 Availability of study data

- 711 The data for the inSCALE project is available on the public repository LSHTM Data Compass under DOI
- 712 https://doi.org/10.17037/DATA.00002559.

713 Funding

- The inSCALE study was supported by grants to JT and BK from The Bill and Melinda Gates Foundation, grant number
- 715 OPP1002407. The BMGF played no role in the design, analysis, decision to publish or preparation of this manuscript.

716 Acknowledgements

- 717 We wish to thank the local research team who collected and managed the data, diMaggi for support in designing the
- app software, the CHWs and supervisors who delivered the intervention, and the participants of the study for their
- time and insight. Funding for this research was provided by the Bill & Melinda Gates Foundation [grant code
- 720 OPP1002407] and UK Department for International Development (UK Aid) through grants to Malaria Consortium, the
- London School of Hygiene and Tropical Medicine, and the Institute for Global Health, University College London for
- the inSCALE project (http://www.malariaconsortium.org/inscale/). The funders participated in the initial discussions
- 723 on intervention design but had no role in the design of the evaluation, data gathering, analysis, interpretation, or
- 724 writing up of the findings. SS, KK, RL, NB, FK and BK had full access to all the data and SS had final responsibility for
- the decision to submit for publication.

- 727
- 728